synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Calmagite is a complexometric indicator used in analytical chemistry to identify the presence of metal ions in solution. As with other metal ion indicators calmagite will change color when it is bound to an ion. Calmagite will be wine red when it is bound to a metal ion and may be blue, red, or orange when it is not bound to a metal ion. Calmagite is often used in conjunction with EDTA, a stronger metal binding agent. This chemical is also used in the quantitation of magnesium in the clinical laboratory.
RCO2H + CH2N2 → RCO2CH3 + N2 Using this diazomethane, mixtures of carboxylic acids can be converted to their methyl esters in near quantitative yields, e.g., for analysis by gas chromatography. The method is useful in specialized organic synthetic operations but is considered too hazardous and expensive for large-scale applications.
== Regulation == Based on research using mice and studies of Ehlers-Danlos syndromes (EDS), which is characterized by hypermobility of the joints, and high levels of skin laxity, researcher found that tenascin X expression levels correlated with the number of present collagen fibrils. In humans, tenascin X is associated with EDS. Through their research, researcher confounded the original hypothesis that tenascin X interfered with collagen fibrillogenesis and suggest that it acts rather as a regulator of collagen fibrillogenesis. Data suggest tenascin is a regulator of collagen fibril spacing. In vitro tests yield evidence that suggest tenascin X accelerates collagen fibril formation through an additive mechanism when collagen VI is present. In addition to tenascin X, multiple proteins, glycoconjugates, and small molecules have shown to influence not only the rate of collagen fibrillogenesis, but also the structure of collagen fibrils as well as their size in lab studies.
Sources: en.wikipedia.org
Subsequently, the Australian government banned pharmacy compounding of GLP-1 medicines, requiring all providers to transition their patients to approved commercial products. In November 2024, Australian regulators and medical experts examined whether advertising by Juniper could indirectly promote prescription-only medicines in breach of the TGA rules. It referred to the use of "medical weight-loss programs" without naming specific drugs, in their advertising. Clinicians and eating-disorder advocates called for stricter oversight of direct-to-consumer marketing in the sector. In 2025, Juniper was among providers whose promotional activity was flagged, including the use of Black Friday sales campaigns and social media engagement. Professional commentary raised concerns about the potential misuse of GLP-1 medications among patients with eating-disorder vulnerabilities. The Australian Health Practitioner Regulation Agency (AHPRA) confirmed that it had taken disciplinary action against individual healthcare practitioners for inappropriate prescribing of GLP-1 receptor agonists to patients, including the issuance of cautions and conditions on registration. During the same period, the TGA requested the removal of more than 3,000 online advertisements for weight-loss medicines, issuing infringement notices for unlawful advertising in September 2025, and releasing updated social-media advertising guidance in November 2025.
=== Hunger === Because patients are being fed intravenously, the subject does not physically eat, resulting in intense hunger pangs (pains). The brain uses signals from the mouth (taste and smell), the stomach and gastrointestinal tract (fullness) and blood (nutrient levels) to determine conscious feelings of hunger. In cases of TPN, the taste, smell and physical fullness requirements are not met, and so the patient experiences hunger, although the body is being fully nourished. Patients who eat food despite the inability can experience a wide range of complications, such as refeeding syndrome.
=== Railway === Several train stations serve Moscow. The city's ten rail terminals (or vokzals) are the following: Belorussky Kazansky Kiyevsky Kursky Leningradsky Paveletsky Rizhsky Savyolovsky Yaroslavsky Vostochny
Sources: en.wikipedia.org
Governor Mike Parson appointed Schmitt as Missouri Attorney General to succeed Josh Hawley, who was elected to the U.S. Senate in 2018. Schmitt took office in January 2019. In 2020, he was elected to a full term. Schmitt resigned as attorney general in 2023 after his election to the U.S. Senate in 2022.
== Clinical significance == The classical presentation of primary HHV-6b infection is as exanthema subitum (ES) or "roseola", featuring a high temperature lasting 3 to 5 days followed by a rash on the torso, neck, or face and sometimes febrile convulsions, however, the symptoms are not always present together. However, one study (1997) indicated that a rash is not a distinguishing feature of HHV-6 infection, with rates similar to non-HHV-6 infections (10–20% of febrile children in both groups). HHV-6 infections more frequently present with high temperatures (over 40C), at a rate of around two thirds compared to less than half in the non-HHV-6 patients. Similarly significant differences were seen in malaise, irritability, and tympanic membrane inflammation. Primary infection in adults tend to be more severe. Diagnosis for the virus, particularly HHV-6B, is vital for the patient because of the infection's adverse effects. Symptoms that point to this infection, such as rashes, go unnoticed in patients that receive antibiotics because they can be misinterpreted as a side-effect of the medicine. In addition to exanthema subitum HHV-6B is known to be associated with the hepatitis, febrile convulsions, and encephalitis. The virus periodically re-activates from its latent state, with HHV-6 DNA being detectable in 20–25% of healthy adults in the United States. In the immunocompetent setting, these re-activations are often asymptomatic, but in immunosuppressed individuals there can be serious complications.
DNA-binding domain (DBD) A protein domain containing at least one structural motif capable of recognizing and interacting with the nucleotides of a double-stranded or single-stranded DNA molecule. DNA-binding domains may bind to specific sequences or have a non-specific affinity for DNA. They are the primary functional components of DNA-binding proteins, including many transcription factors and regulatory proteins.
Primary structure the linear amino acid sequence of a protein, which chemically is a polypeptide chain composed of amino acids joined by peptide bonds. Profile (sequence context) a scoring matrix that represents a multiple sequence alignment of a protein family. The profile is usually obtained from a well-conserved region in a multiple sequence alignment. The profile is in the form of a matrix with each column representing a position in the alignment and each row one of the amino acids. Matrix values give the likelihood of each amino acid at the corresponding position in the alignment. The profile is moved along the target sequence to locate the best scoring regions by a dynamic programming algorithm. Gaps are allowed during matching and a gap penalty is included in this case as a negative score when no amino acid is matched. A sequence profile may also be represented by a hidden Markov model, referred to as a profile HMM. Profile (structural context) a scoring matrix that represents which amino acids should fit well and which should fit poorly at sequential positions in a known protein structure. Profile columns represent sequential positions in the structure, and profile rows represent the 20 amino acids. As with a sequence profile, the structural profile is moved along a target sequence to find the highest possible alignment score by a dynamic programming algorithm. Gaps may be included and receive a penalty. The resulting score provides an indication as to whether or not the target protein might adopt such a structure.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.